Header Logo

Connection

Gary Raskob to Venous Thromboembolism

Back to Details
This is a "connection" page, showing publications Gary Raskob has written about Venous Thromboembolism.
Gary Raskob
Connection Strength
19.582
Venous Thromboembolism
  1. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc. 2022 10 18; 11(20):e026229.
    View in: PubMed
    Score: 0.715
  2. Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. J Thromb Haemost. 2022 10; 20(10):2366-2378.
    View in: PubMed
    Score: 0.707
  3. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 11 16; 10(22):e021579.
    View in: PubMed
    Score: 0.671
  4. Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma. Thromb Haemost. 2021 Jun; 121(6):816-825.
    View in: PubMed
    Score: 0.634
  5. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. Oncologist. 2021 01; 26(1):e8-e16.
    View in: PubMed
    Score: 0.629
  6. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020 06 30; 75(25):3140-3147.
    View in: PubMed
    Score: 0.611
  7. Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thromb Haemost. 2020 Jun; 120(6):924-936.
    View in: PubMed
    Score: 0.608
  8. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):130-139.
    View in: PubMed
    Score: 0.592
  9. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thromb Res. 2020 01; 185:13-19.
    View in: PubMed
    Score: 0.584
  10. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874.
    View in: PubMed
    Score: 0.573
  11. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619886022.
    View in: PubMed
    Score: 0.551
  12. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.
    View in: PubMed
    Score: 0.535
  13. Edoxaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 07 05; 379(1):95-96.
    View in: PubMed
    Score: 0.532
  14. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
    View in: PubMed
    Score: 0.512
  15. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017 08 30; 117(9):1662-1670.
    View in: PubMed
    Score: 0.495
  16. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug; 3(8):e379-87.
    View in: PubMed
    Score: 0.463
  17. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36.
    View in: PubMed
    Score: 0.454
  18. Global public awareness of venous thromboembolism: reply. J Thromb Haemost. 2016 05; 14(5):1111-2.
    View in: PubMed
    Score: 0.453
  19. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 06 02; 115(6):1240-8.
    View in: PubMed
    Score: 0.450
  20. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16.
    View in: PubMed
    Score: 0.445
  21. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016 Jan; 137:3-10.
    View in: PubMed
    Score: 0.444
  22. The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods. Am Heart J. 2015 Sep; 170(3):447-54.e18.
    View in: PubMed
    Score: 0.430
  23. Oral anticoagulants: new and improved. Blood. 2014 Sep 18; 124(12):1851-2.
    View in: PubMed
    Score: 0.409
  24. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94.
    View in: PubMed
    Score: 0.376
  25. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64.
    View in: PubMed
    Score: 0.341
  26. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
    View in: PubMed
    Score: 0.305
  27. Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800.
    View in: PubMed
    Score: 0.255
  28. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 04 07; 44(14):1231-1244.
    View in: PubMed
    Score: 0.185
  29. Redefining clinical venous thromboembolism phenotypes: a?novel approach using latent class analysis. J Thromb Haemost. 2023 03; 21(3):573-585.
    View in: PubMed
    Score: 0.181
  30. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 05 10; 145(19):1471-1479.
    View in: PubMed
    Score: 0.173
  31. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
    View in: PubMed
    Score: 0.168
  32. Abelacimab for Prevention of Venous Thromboembolism. Reply. N Engl J Med. 2021 11 04; 385(19):1822-1823.
    View in: PubMed
    Score: 0.168
  33. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 10; 174(10):1420-1429.
    View in: PubMed
    Score: 0.166
  34. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021 12; 19(12):3008-3017.
    View in: PubMed
    Score: 0.166
  35. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021 11; 19(11):2801-2813.
    View in: PubMed
    Score: 0.165
  36. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021 11; 19(11):2772-2780.
    View in: PubMed
    Score: 0.165
  37. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
    View in: PubMed
    Score: 0.164
  38. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211053316.
    View in: PubMed
    Score: 0.158
  39. Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J. 2020 02; 55(2).
    View in: PubMed
    Score: 0.149
  40. Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. Thromb Res. 2019 Dec; 184:58-61.
    View in: PubMed
    Score: 0.146
  41. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088.
    View in: PubMed
    Score: 0.145
  42. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
    View in: PubMed
    Score: 0.138
  43. Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 12 06; 379(23):2280.
    View in: PubMed
    Score: 0.137
  44. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
    View in: PubMed
    Score: 0.134
  45. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thromb Res. 2018 10; 170:75-83.
    View in: PubMed
    Score: 0.134
  46. Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul; 118(7):1270-1278.
    View in: PubMed
    Score: 0.132
  47. Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thromb Haemost. 2018 01; 118(1):174-181.
    View in: PubMed
    Score: 0.129
  48. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 02; 162:7-14.
    View in: PubMed
    Score: 0.128
  49. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
    View in: PubMed
    Score: 0.128
  50. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. Thromb Haemost. 2017 Oct; 117(10):1944-1951.
    View in: PubMed
    Score: 0.128
  51. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost. 2017 10 05; 117(10):1944-1951.
    View in: PubMed
    Score: 0.125
  52. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017 04 03; 117(4):784-793.
    View in: PubMed
    Score: 0.121
  53. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 01 26; 117(2):415-421.
    View in: PubMed
    Score: 0.119
  54. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep; 3(9):e437-45.
    View in: PubMed
    Score: 0.117
  55. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30; 116(6):1159-1164.
    View in: PubMed
    Score: 0.117
  56. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 Sep 27; 116(4):747-53.
    View in: PubMed
    Score: 0.116
  57. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. Chest. 2016 Nov; 150(5):1059-1068.
    View in: PubMed
    Score: 0.115
  58. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost. 2016 07 04; 116(1):155-61.
    View in: PubMed
    Score: 0.114
  59. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec; 13(12):2187-91.
    View in: PubMed
    Score: 0.110
  60. Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71.
    View in: PubMed
    Score: 0.108
  61. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15.
    View in: PubMed
    Score: 0.095
  62. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808.
    View in: PubMed
    Score: 0.094
  63. Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol. 2013 Apr; 32(2):111-260.
    View in: PubMed
    Score: 0.092
  64. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar; 11(3):444-51.
    View in: PubMed
    Score: 0.092
  65. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708.
    View in: PubMed
    Score: 0.090
  66. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011 May 24; 342:d3036.
    View in: PubMed
    Score: 0.081
  67. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98.
    View in: PubMed
    Score: 0.079
  68. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
    View in: PubMed
    Score: 0.078
  69. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 06; 375(9717):807-15.
    View in: PubMed
    Score: 0.075
  70. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604.
    View in: PubMed
    Score: 0.072
  71. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
    View in: PubMed
    Score: 0.070
  72. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
    View in: PubMed
    Score: 0.066
  73. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 01; 25(34):5490-505.
    View in: PubMed
    Score: 0.063
  74. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar; 120(3):515-524.
    View in: PubMed
    Score: 0.037
  75. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
    View in: PubMed
    Score: 0.034
  76. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510.
    View in: PubMed
    Score: 0.020
  77. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 Aug; 122(8):762-769.e3.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.